Combining radiation therapy, CART-19 therapy, and gut microbiome changes to treat lymphoma
Official title: Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation
Funded at University of Pennsylvania · NIH-11049595 · Data updated 2026-11-12
This study is exploring a new way to treat lymphoma by using a combination of radiation therapy, a special immune treatment called CART-19, and an antibiotic to adjust the gut bacteria, all aimed at helping your body fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $667,533 |
| NIH project number | 1R01CA288473-01A1 |
| Project ID | NIH-11049595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lymphoma who are eligible for radiation therapy and CART-19 therapy.
✕Less likely to help
Patients with other types of cancer or those who are not eligible for radiation or CART-19 therapy may not benefit from this research.
What this research studies
This research investigates a novel approach to treating lymphoma by combining radiation therapy with CART-19 therapy and modulation of the gut microbiome using oral Vancomycin. The study aims to enhance the body's immune response against tumors by selectively depleting certain gut bacteria, which may improve the presentation of tumor-associated antigens to immune cells. Patients will be monitored for improvements in tumor response and overall survival as a result of this combined treatment strategy. The research builds on previous findings that showed promising results in preclinical models and early-stage clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for lymphoma patients, potentially improving survival rates and quality of life.
How similar studies have gone: Previous studies have shown success with similar approaches, particularly in enhancing antitumor responses through gut microbiome modulation and combination therapies.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Facciabene, Andrea — University of Pennsylvania
- Study coordinator: Facciabene, Andrea
Related research
Other NIH-funded projects on the same topics.
-
Gut bacteria and treatment outcomes in lymphoma
Seeing whether the mix of gut bacteria relates to treatment success and immune responses in people with diffuse large B‑cell lymphoma.
-
Combining radiation, CAR‑T (CART‑19), and gut microbiome changes to treat B‑cell lymphoma
This project uses radiation, CART‑19 cell therapy, and a short course of oral vancomycin to try to improve outcomes for people with B‑cell lymphoma.
-
Investigating how gut bacteria affect lymphoma treatment outcomes and immune response
This study is looking at how the bacteria in your gut might affect how well treatment works for people with diffuse large B-cell lymphoma, and it hopes to find ways to personalize therapies based on your unique gut health.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.